HF50

Phase 1Small molecule

HHighField Biopharmaceuticals Corporation

HF50 is one of 66 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Advanced Solid TumorsRecruiting

Solid TumorPhase 1

Recruiting

Advanced Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

Fludara

Sanofi

Preclinical

2 4

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 5

Navmi

SSummit Therapeutics

Preclinical

1 6

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 7

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

Soc

Pfizer

Preclinical

1 10

Interleukin 2

EEssen Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Solid Tumor

NCT07601334

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

Recruiting·HHighField Biopharmaceuticals Corporation·Phase 1·NCT06822998·10 enrolled

Solid Tumor1 trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of HF50 in Patients With Advanced Solid Tumors

Recruiting·HHighField Biopharmaceuticals Corporation·Phase 1·NCT07601334·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HF50. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HF50 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HF50. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HighField Biopharmaceuticals Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHighField Biopharmaceuticals Corporation

HF50

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Advanced Solid Tumors1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News